Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting

About this update from Arrowhead Pharmaceuticals, Inc.

[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, also known as TAK-999, the company’s second-generation investigational RNA interference (RNAi) therapeutic being co-developed with Takeda Pharmaceutical Company Limited (\"Takeda”) as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). The data were presented in a late-breaking poster at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), taking place November 12-15, 2021.\n\nKey data presented include the following:\n\nPharmacodynamic Response\n\n\nARO-AAT treatment allowed clearance of liver Z-AAT protein\n\n\nTotal liver Z-AAT was reduced by 72-100%\n\n\n\n\nARO-AAT treatment improved liver fibrosis\n\n\n6 of 14 patients had a 1 point or greater improvement in METAVIR fibrosis stage from baseline to week 24 or 48\n\n\n6 of 14 patients had no change from baseline to week 24 or 48\n\n\n2 of 14 patients had an increase from F2 at baseline to F3 at week 48, although both patients had profound reduction in PAS+D globule burden and reduced ALT and GGT after treatment\n\n\n\n\nARO-AAT treatment reduced histological globule burden\n\n\n13 of 13 patients had a 1 point or greater reduction in PAS+D globule burden\n\n\n\n\nARO-AAT treatment improved biomarkers of liver health\n\n\nMean reduction from baseline ranged from 42% to 56% for ALT and from 33% to 54% for GGT at week 28 and week 72\n\n\nAll groups showed normalized ALT and GGT following treatment\n\n\n\n\nSafety\n\n\nNo treatment emergent adverse events leading to drug discontinuation, dose interruptions, or study withdrawal\n\n\nNo treatment emergent adverse events related to change in pulmonary status or pulmonary function were reported\n\n\nNo clinically meaningful changes in ppFEV1 from baseline (mean 85% [N=16]) were observed at Week 40 (mean 81% [N=15]) or at Week 72 (mean 84% [N=4])\n\n\nFour SAEs were reported: EBV-related myocarditis, diverticulitis, dyspnea, and vestibular neuronitis, all of which involve confounding factors or alternative etiology\n\n\nA copy of the poster may be accessed on the Events and Presentations page under the Investors section ...

More updates from Arrowhead Pharmaceuticals, Inc.